Core Insights - TuHURA Biosciences, Inc. is advancing its Phase 3 immune-oncology initiatives, focusing on overcoming resistance to cancer immunotherapy [5][6] - The company announced that abstracts from Kineta Inc. and Moffitt Cancer Center will be presented at the AACR Annual Meeting 2025, showcasing novel therapies for advanced melanoma [1][2] Group 1: Company Developments - TuHURA is set to present initial results from a Phase 1 study of KVA12123, an anti-VISTA antibody, in combination with pembrolizumab for advanced solid tumors [2] - The company is preparing to initiate a Phase 3 trial for its lead product, IFx-2.0, as an adjunctive therapy to Keytruda® for advanced Merkel Cell Carcinoma [6] - TuHURA has entered into a merger agreement with Kineta, Inc. to acquire the rights to KVA12123, with the merger expected to close in Q2 2025 [4] Group 2: Research and Presentations - The accepted abstracts for the AACR Annual Meeting include mechanistic insights into IFx-Hu2.0 responses after prior anti-PD-1 therapy failure [2] - Presentations will take place on April 28, 2025, with specific sessions dedicated to experimental therapeutics and immunology [2][3]
TuHURA Biosciences, Inc. Announces Abstracts Accepted for Poster Presentation at the 2025 AACR Annual Meeting